Barclays PLC Buys 45,402 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Barclays PLC lifted its stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHATFree Report) by 366.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 57,807 shares of the company’s stock after acquiring an additional 45,402 shares during the period. Barclays PLC owned approximately 0.08% of Phathom Pharmaceuticals worth $1,044,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its position in Phathom Pharmaceuticals by 7.1% during the third quarter. Geode Capital Management LLC now owns 862,918 shares of the company’s stock valued at $15,605,000 after buying an additional 56,871 shares during the period. MML Investors Services LLC boosted its holdings in Phathom Pharmaceuticals by 72.8% during the 3rd quarter. MML Investors Services LLC now owns 33,860 shares of the company’s stock valued at $612,000 after acquiring an additional 14,260 shares during the period. State Street Corp grew its position in Phathom Pharmaceuticals by 17.5% during the 3rd quarter. State Street Corp now owns 922,788 shares of the company’s stock worth $16,684,000 after acquiring an additional 137,539 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Phathom Pharmaceuticals in the 3rd quarter worth approximately $7,952,000. Finally, Portolan Capital Management LLC lifted its position in Phathom Pharmaceuticals by 50.4% in the third quarter. Portolan Capital Management LLC now owns 1,699,918 shares of the company’s stock valued at $30,735,000 after purchasing an additional 569,829 shares during the last quarter. 99.01% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Phathom Pharmaceuticals

In related news, Director Frank Karbe purchased 12,500 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was bought at an average cost of $7.93 per share, with a total value of $99,125.00. Following the completion of the purchase, the director now directly owns 57,000 shares in the company, valued at approximately $452,010. This represents a 28.09 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 24.10% of the company’s stock.

Phathom Pharmaceuticals Stock Up 2.6 %

NASDAQ:PHAT opened at $6.79 on Wednesday. The firm’s fifty day simple moving average is $8.96 and its 200 day simple moving average is $12.69. The stock has a market cap of $464.28 million, a P/E ratio of -1.19 and a beta of 0.56. Phathom Pharmaceuticals, Inc. has a twelve month low of $6.07 and a twelve month high of $19.71.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Thursday, December 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Friday, January 10th.

Read Our Latest Analysis on Phathom Pharmaceuticals

Phathom Pharmaceuticals Company Profile

(Free Report)

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.

Featured Articles

Institutional Ownership by Quarter for Phathom Pharmaceuticals (NASDAQ:PHAT)

Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.